1. MAPK/ERK Pathway
  2. JNK

Anisomycin (Synonyms: Flagecidin; Wuningmeisu C)

Cat. No.: HY-18982 Purity: 98.03%
Handling Instructions

Anisomycin is a potent c-Jun N-terminal kinase (JNK) activator.

For research use only. We do not sell to patients.

Anisomycin Chemical Structure

Anisomycin Chemical Structure

CAS No. : 22862-76-6

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 66 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
10 mg USD 60 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
50 mg USD 120 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
100 mg USD 180 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

    Anisomycin purchased from MCE. Usage Cited in: Biochem Biophys Res Commun. 2018 May 23;499(4):743-750.

    Astrocytes are cultured with p38 and JNK activator of DHC and ANS, respectively, at the indicated concentrations for 24 h. Then, all cells are harvested for western blot analysis of p-p38 and p-JNK. Astrocytes are pretreated with DHC (500 nM) or ANS (10 mM) for 24 h, followed by Fru (5 mM) for an additional 24 h.

    Anisomycin purchased from MCE. Usage Cited in: Sci Rep. 2018 Apr 23;8(1):6379.

    Immunoblot analysis of lysates from Anisomycin pre-treatment cells reveals an increase of CHIP protein compared with OGD treated only cells, contrasting with a decrease in RIPK3 and p-MLKL protei. Pre-treatment cells with SP600125 results in the expected attenuation in JNK phosphorylation levels.

    Anisomycin purchased from MCE. Usage Cited in: Am J Physiol Cell Physiol. 2018 May 2.

    Western blot analysis shows that inhibiting MAPK cannot completely reverse increased expression of RNF2 and cisplatin resistance of OC cells.

    View All JNK Isoform Specific Products:

    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Anisomycin is a potent c-Jun N-terminal kinase (JNK) activator.

    IC50 & Target[1]

    JNK

     

    In Vitro

    To examine whether JNK has a core role in colistin-induced neurotoxicity in PC-12 cells, an SP600125 (a highly selective inhibitor of JNK) and Anisomycin (a potent activator) are used in this study. In order to select an appropriate concentration, PC-12 cells are treated with a range of SP600125 (0-80 μM) and Anisomycin (0-20 μM) respectively for 24 h. The results show that the cells viability significantly decreases by SP600125 treatment in a concentration-dependent manner, observed at the concentrations greater than 20 μM (p<0.01). Similarly the cells viability is inhibited by Anisomycin treatment (≥8 μM) (p<0.05) [1].

    In Vivo

    Disruption of TNFRp55/p75 attenuates Anisomycin-induced ventricular functional improvements. Anisomycin results in an improvement in left ventricular developed pressure (LVDP), which disappears in animals with disruption of TNFR p55/p75. In addition, the Anisomycin-induced improvement in LVEDP in wild-type animals is eliminated by deletion of TNFR p55/p75. Likewise, disruption of TNFR p55/p75 abrogates the recovery of rate pressure product (RPP) elicited by pretreatment of Anisomycin. TNFR p55/p75-/- mice without Anisomycin treatment do not show differences in cardiac functional recovery compared with the control wild-type mice. There are no significant differences in heart rate between wild-type and TNFR p55/p75-deficient mice. To see whether Nox2 is involved in Anisomycin-induced myocardial protection, Nox2-deficient mice are treated with Anisomycin. The improvement in the LVEDP in Anisomycin-treated mice is eliminated in Nox2-/- mice compared with wild-type mice. In addition, recovery of RPP in wild-type mice treated with Anisomycin is mitigated in Nox2-/- mice. Nox2-/- mice without Anisomycin treatment do not show the difference in cardiac functional recovery compared with wild-type control mice[2].

    References
    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 3.7692 mL 18.8459 mL 37.6918 mL
    5 mM 0.7538 mL 3.7692 mL 7.5384 mL
    10 mM 0.3769 mL 1.8846 mL 3.7692 mL
    Please refer to the solubility information to select the appropriate solvent.
    Cell Assay
    [1]

    PC-12 cells are seeded in 96-well plates at a concentration of 1×104 cells/well and cultured in an incubator at 37°C with 5% CO2 for at least 12 h prior to exposure to different concentrations of SP600125 (0-80 μM) or Anisomycin (0-20 μM) for 24 h. Subsequently, the culture medium is added to 20 μL of 5 mg/mL MTT working solution and the plate is incubated for 2 h at 37°C. The culture supernatant is removed and the formazan crystals are dissolved in 150 μL DMSO. Finally, the absorbance of each well is measured at 490 nm by a microplate reader. Cell viability is expressed as the percentage of the control group, which is set to 100%[1].
    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [2]

    Mice[2]
    Adult male TNFRp55/p75 mice, adult male wild-type C57/BL and homozygous Nox2-/- mice are used in this study. Mice are randomized into six experimental groups that undergo the following treatments,. Animals are divided into six groups: group 1: control ischemia/reperfusion, wild-type mice are injected with DMSO (0.1 mL); group 2: Anisomycin+wild-type mice, wild-type mice are injected with Anisomycin (0.1 mg/kg ip); group 3: Anisomycin+TNFR p55/p75-/- mice, TNFR p55/75-/- mice are injected with Anisomycin (0.1 mg/kg ip); group 4: TNFR p55/p75-/- mice, TNFR p55/75-/- mice are not injected with Anisomycin; group 5: Anisomycin+Nox2-/- mice, Nox2-/- mice are injected with Anisomycin (0.1 mg/kg ip); and group 6: Nox2-/- mice, Nox2-/- mice are not injected with Anisomycin. Later (24 h), the hearts are subjected to 30 min of ischemia followed by 30 min of reperfusion[2].
    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    265.31

    Formula

    C₁₄H₁₉NO₄

    CAS No.

    22862-76-6

    SMILES

    O[[email protected]@H]1[[email protected]@H](OC(C)=O)[[email protected]@H](CC2=CC=C(OC)C=C2)NC1

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    10 mM in DMSO

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Purity: 98.03%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country or Region *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Anisomycin
    Cat. No.:
    HY-18982
    Quantity: